|
| | 3-(1-Methyl-1H-pyrazol-4-yl)-5-oxo-N-(2-pyridinylmethyl)-5H-benzo[4,5]cyclohepta[1,2-b]pyridine-7-methanesulfonamide Basic information |
| | 3-(1-Methyl-1H-pyrazol-4-yl)-5-oxo-N-(2-pyridinylmethyl)-5H-benzo[4,5]cyclohepta[1,2-b]pyridine-7-methanesulfonamide Chemical Properties |
| Boiling point | 761.0±70.0 °C(Predicted) | | density | 1.39 | | storage temp. | Store at -20°C | | solubility | Soluble in DMSO | | pka | 8.93±0.40(Predicted) | | form | Powder |
| | 3-(1-Methyl-1H-pyrazol-4-yl)-5-oxo-N-(2-pyridinylmethyl)-5H-benzo[4,5]cyclohepta[1,2-b]pyridine-7-methanesulfonamide Usage And Synthesis |
| Uses | MK 8033 is a novel and specific dual ATP competitive c-Met/Ron inhibitor and is used in the treatment of cancer. |
| | 3-(1-Methyl-1H-pyrazol-4-yl)-5-oxo-N-(2-pyridinylmethyl)-5H-benzo[4,5]cyclohepta[1,2-b]pyridine-7-methanesulfonamide Preparation Products And Raw materials |
|